John Wheeler
26Patents
6h-index
76Co-inventors
68Inventor score
Filing activity: Aug 25, 2009 → Mar 30, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9102737B2 | Human anti-CD27 antibodies, methods and uses | Chemistry; Metallurgy | 26 | Active |
| US9090694B2 | ST2L antibody antagonists | Chemistry; Metallurgy | 18 | Active |
| US9212227B2 | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions | Chemistry; Metallurgy | 12 | Active |
| US9850310B2 | CD123 binding agents and uses thereof | Chemistry; Metallurgy | 12 | Active |
| US8394378B2 | Antibodies binding human collagen II | Chemistry; Metallurgy | 10 | Active |
| US9683046B2 | Nucleic acid molecules encoding anti-CD27 antibodies | Chemistry; Metallurgy | 7 | Active |
| US8785605B2 | Humanized IL-25 antibodies | Chemistry; Metallurgy | 4 | Active |
| US9951137B2 | ST2L antagonists and methods of use | Chemistry; Metallurgy | 2 | Active |
| US10301392B2 | Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies | Chemistry; Metallurgy | 2 | Active |
| US10450377B2 | ST2L antagonists and methods of use | Chemistry; Metallurgy | 1 | Active |
| US10829549B2 | Anti-CCL17 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US9944697B2 | Anti-CCL17 antibodies | Emerging Cross-Sectional Technologies | 1 | Active |
| US10633435B2 | Anti-PHF-tau antibodies and uses thereof | Physics | 0 | Active |
| US11414484B2 | Anti-CCL17 antibodies | Emerging Cross-Sectional Technologies | 0 | Active |
| US9062305B2 | Generation of human de novo pIX phage display libraries | Chemistry; Metallurgy | 0 | Active |
| US8906649B2 | Antibodies binding human collagen II | Chemistry; Metallurgy | 0 | Active |
| US9808649B2 | Immobilization system to support an in vivo medical device | Human Necessities | 0 | Active |
| US12269888B2 | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US10689453B2 | Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies | Chemistry; Metallurgy | 0 | Active |
| US12234280B2 | Anti-PHF-tau antibodies and uses thereof | Physics | 0 | Active |
| US11661459B2 | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US10207856B2 | Liquid release device | Performing Operations; Transporting | 0 | Active |
| US11732050B2 | Neutralizing human anti-CD27 antibodies | Chemistry; Metallurgy | 0 | Active |
| US8822423B2 | Affinity peptides toward infliximab | Chemistry; Metallurgy | 0 | Active |
| US11883432B2 | Chimeric antigen receptor system with adaptable receptor specificity | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.